Vivo Capital’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
Other funds holding SABS
Vivo Capital's SABS Position: Q3 2026 in Review
Vivo Capital reduced its SAB Biotherapeutics (SABS) stake by 5.3% in Q3 2026, selling an estimated $1.4M and leaving 6,915,011 shares worth $21.9M. The position accounts for 2.41% of the portfolio, ranked #17.
Vivo Capital first reported a position in SABS in Q3 2025 and has held it in 5 quarters since. The position peaked at $43.7M in Q1 2026. 102 funds tracked by Wall St. Rank hold SABS as of Q3 2026.
- Vivo Capital held 6,915,011 shares of SAB Biotherapeutics worth $21.9M as of Q3 2026.
- Vivo Capital sold 384,898 SAB Biotherapeutics shares in Q3 2026, an estimated $1.4M.
- SAB Biotherapeutics made up 2.41% of Vivo Capital's portfolio in Q3 2026, its #17 holding.
- Vivo Capital first reported a position in SAB Biotherapeutics in Q3 2025 and has held it in 5 quarters since.
- Vivo Capital's SAB Biotherapeutics position peaked at $43.7M in Q1 2026.
- 102 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.
Based on Vivo Capital's 13F filing for Q3 2026, filed 13 Nov 2026.